Analyst Serge Belanger from Needham maintained a Buy rating on Liquidia Technologies and increased the price target to $36.00 from $32.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Serge Belanger has given his Buy rating due to a combination of factors that highlight the promising outlook for Liquidia Technologies. The company’s second-quarter earnings for 2025 showcased a robust start for Yutrepia, with sales figures exceeding initial expectations. This strong performance was marked by impressive prescription numbers and treatment initiations, indicating a positive reception in the market.
Furthermore, the early success of Yutrepia is attributed to its unique profile, which offers improved tolerability and higher dosage levels, setting it apart as a leading option in its class. As awareness and insurance coverage expand in the latter half of the year, sales growth is expected to accelerate. These factors have led to an increased price target, reflecting the anticipated continued success of Yutrepia.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $54.00 price target.